IL199992A0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
IL199992A0
IL199992A0 IL199992A IL19999209A IL199992A0 IL 199992 A0 IL199992 A0 IL 199992A0 IL 199992 A IL199992 A IL 199992A IL 19999209 A IL19999209 A IL 19999209A IL 199992 A0 IL199992 A0 IL 199992A0
Authority
IL
Israel
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
IL199992A
Other languages
English (en)
Original Assignee
Gloucester Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gloucester Pharmaceuticals Inc filed Critical Gloucester Pharmaceuticals Inc
Publication of IL199992A0 publication Critical patent/IL199992A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL199992A 2007-01-23 2009-07-21 Combination therapy IL199992A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88616907P 2007-01-23 2007-01-23
US577407P 2007-12-07 2007-12-07
PCT/US2008/000850 WO2008091620A2 (en) 2007-01-23 2008-01-23 Combination therapy comprising romidepsin and i.a. bortezomib

Publications (1)

Publication Number Publication Date
IL199992A0 true IL199992A0 (en) 2010-04-15

Family

ID=39323892

Family Applications (1)

Application Number Title Priority Date Filing Date
IL199992A IL199992A0 (en) 2007-01-23 2009-07-21 Combination therapy

Country Status (8)

Country Link
US (1) US20090105200A1 (https=)
EP (1) EP2117556A2 (https=)
JP (1) JP2010516767A (https=)
AU (1) AU2008209555A1 (https=)
CA (1) CA2676387A1 (https=)
IL (1) IL199992A0 (https=)
MX (1) MX2009007777A (https=)
WO (1) WO2008091620A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
KR20160091440A (ko) * 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
CA2763471A1 (en) * 2009-05-27 2010-12-02 Cephalon, Inc. Combination therapy for the treatment of multiple myeloma
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CN102946879B (zh) * 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
EP3352793A1 (en) * 2015-09-21 2018-08-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare New therapeutic strategies against blood cancer
EP3380086B1 (en) 2015-11-25 2021-10-13 IO Therapeutics, Inc. Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
CN119698276A (zh) * 2022-06-07 2025-03-25 蓝腾制药公司 用酰基富烯与依鲁替尼或硼替佐米的组合治疗癌症

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2238982T1 (sl) * 2003-06-27 2013-01-31 Astellas Pharma Inc. Terapevtsko sredstvo za mehkotkivni sarkom
JP2009539862A (ja) * 2006-06-09 2009-11-19 メリオン リサーチ Ｉｉｉ リミテッド 強化剤を含む固体経口投与剤形
AU2007296259A1 (en) * 2006-09-15 2008-03-20 Janssen Pharmaceutica Nv Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors

Also Published As

Publication number Publication date
US20090105200A1 (en) 2009-04-23
WO2008091620A3 (en) 2008-09-18
JP2010516767A (ja) 2010-05-20
WO2008091620A2 (en) 2008-07-31
EP2117556A2 (en) 2009-11-18
MX2009007777A (es) 2009-12-16
AU2008209555A1 (en) 2008-07-31
CA2676387A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
IL206654A0 (en) Combination therapy
IL196559A0 (en) Combination therapy
IL199992A0 (en) Combination therapy
GB2464440B (en) Massager
IL201235A0 (en) Therapeutic agents
IL196556A0 (en) Combination therapy
EP2054061A4 (en) COMBINATION THERAPY
EP2247319A4 (en) THERAPY DEVICE
GB0723747D0 (en) Therapeutic agents
GB0719518D0 (en) Therapy
ZA200902203B (en) Combination therapy
EP2211863A4 (en) COMBINATION THERAPY
GB0700284D0 (en) Combination therapy
GB0803948D0 (en) Combination therapy
GB0700635D0 (en) Therapy
GB0808690D0 (en) Therapeutic use
GB0723748D0 (en) Therapeutic agents
GB0716072D0 (en) Therapy
GB0703963D0 (en) Therapy
GB0705917D0 (en) Therapy
GB0721011D0 (en) New therapy
GB0721009D0 (en) New therapy
GB0721010D0 (en) New therapy
GB0721012D0 (en) New therapy
GB0610706D0 (en) Combination therapy